UK GMC proposes costs can be considered when prescribing off-label

7 April 2011

For the first time, the UK’s General Medical Council GMC is proposing that doctors can prescribe a cheaper off-label alternative to a licensed medicine, as long as it is approved in authoritative clinical guidelines and is just as safe and effective for the patient.

The GMC’s Good practice in prescribing and managing medicines and devices puts forward new standards designed to make prescribing safer for patients and support doctors in managing medicines. Patients buying prescriptions on-line would receive greater protection under the guidance, which would require doctors prescribing via web sites to liaise with the patient’s general practitioners, unless the patient objects.

Doctors are also being asked to raise and to respond constructively to concerns raised by colleagues and patients about adverse incidents and near-misses involving the use of medicines and medical devices.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight



More Features in Pharmaceutical